Long-term functional outcomes in patients with a W-shaped ileal orthotopic neobladder with no antireflux mechanism.

OBJECTIVE: To evaluate the long-term renal function, continence, and voiding function in 64 patients, surviving for 5 or more years after W-shaped ileal neobladder with a short afferent limb and refluxing ureterointestinal anastomoses. MATERIALS AND METHODS: Kidney morphology and function were evaluated using nuclear renography, creatinine, and glomerular filtration rate. Continence and voiding function were evaluated with a diary on frequency, voided volumes, number of pads, and with the incontinence severity index (ISI) questionnaire, the American Urological Association-Symptom Index (AUA-SI), and the American Urological Association-Symptom Problem Index. RESULTS: The renal scan showed a dilatation of the upper urinary tract in 4.8% of renoureteral units. Of the patients, 12.5% voided with intermittent or permanent catheterization. The remaining 87.5% voided spontaneously; 75% did not use pads, 12.5% used protection for safety, 7.1% 1 pad, and 5.4% more than 1 pad, during the day; during night, 55.3% did not use pads, 23.2% used protection for safety, and 12.6% and 8.9% 1 or more than 1 pad. The ISI questionnaire showed that 35.7% were fully continent, whereas 41%, 12.5%, and 10.8% had slight, moderate, and severe incontinence. The AUA-SI showed that 50% had mild, 39.3% moderate, and 10.7% severe lower urinary tract symptoms. Urinary incontinence, daytime frequency, and nocturia correlated positively with the age of patients at follow-up and negatively with voided volume. CONCLUSION: Long-term detrimental effect on renal function of orthotopic neobladder with no antireflux anastomoses is limited. Long-term continence and voiding function results are satisfactory. The ISI questionnaire might be useful to evaluate and grade incontinence in patients with orthotopic neobladder, whereas the AUA-SI has many limitations.

Results of vardenafil mediated power Doppler ultrasound, contrast enhanced ultrasound and systematic random biopsies to detect prostate cancer.

PURPOSE: We evaluated the ability of the phosphodiesterase-5 inhibitor vardenafil to increase prostate microcirculation during power Doppler ultrasound. We also evaluated the results of contrast and vardenafil enhanced targeted biopsies compared to those of standard 12-core random biopsies to detect cancer. MATERIALS AND METHODS: Between May 2008 and January 2010, 150 consecutive patients with prostate specific antigen more than 4 ng/ml at first diagnosis with negative digital rectal examination and transrectal ultrasound, and no clinical history of prostatitis underwent contrast enhanced power Doppler ultrasound (bolus injection of 2.4 ml SonoVue® contrast agent), followed by vardenafil enhanced power Doppler ultrasound (1 hour after oral administration of vardenafil 20 mg). All patients underwent standard 12-core transrectal ultrasound guided random prostate biopsy plus 1 further sampling from each suspected hypervascular lesion detected by contrast and vardenafil enhanced power Doppler ultrasound. RESULTS: Prostate cancer was detected in 44 patients (29.3%). Contrast and vardenafil enhanced power Doppler ultrasound detected suspicious, contrast enhanced and vardenafil enhanced areas in 112 (74.6%) and 110 patients (73.3%), and was diagnostic for cancer in 32 (28.5%) and 42 (38%), respectively. Analysis of standard technique, and contrast and vardenafil enhanced power Doppler ultrasound findings by biopsy core showed significantly higher detection using vardenafil vs contrast enhanced power Doppler ultrasound and standard technique (41.2% vs 22.7% and 8.1%, p <0.005 and <0.001, respectively). The detection rate of standard plus contrast or vardenafil enhanced power Doppler ultrasound was 10% and 11.7% (p not significant). CONCLUSIONS: Vardenafil enhanced power Doppler ultrasound enables excellent visualization of the microvasculature associated with cancer and can improve the detection rate compared to contrast enhanced power Doppler ultrasound and the random technique.

Treatment with intraoperative Patent Blue V dye of refractory lymphocele after inguinal lymphadenectomy for squamous cell penile carcinoma.

OBJECTIVES: To evaluate the potential curative role of the intraoperative use of a dye, the Patent Blue V, for the treatment of refractory lymphoceles by mapping the lymphatic leakage and selectively ligating the opened lymphatics. Inguinal lymphocele is a well-known complication after inguinofemoral lymph node dissection for penile cancer, and a variety of curative approaches have been reported. METHODS: From 1995 to 2007, 40 patients had undergone partial or total penectomy for squamous cell cancer. Superficial inguinal lymph node dissection with saphenous vein sparing or deep lymph node dissection was performed in 15 patients. It was unilateral in 14 and bilateral in 1 patient. When the lymphoceles were refractory to conventional therapy, ligation of the lymphatic vessels after mapping of the leakage with the Patent Blue V dye was the treatment of choice. RESULTS: Overall, 5 lymphoceles were detected in 4 patients that were continuously increasing in size after discharge and were treated conventionally. In the 2 refractory lymphoceles, we then opted for the intraoperative use of a dye, the Patent Blue V, to map the lymphatic leakage and selectively ligate the opened lymphatics. In both cases, complete resolution of the lymphoceles occurred. No complications were observed with this technique. CONCLUSIONS: The presented technique is able to cure persistent lymphoceles refractory to conventional treatment after inguinal lymph node dissection.